Eccogene
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Zhangjiang hi-Tech Park Pudong District ...Website
www.eccogene.comRevenue
$19.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Eccogene
Eccogene is a clinical stage biopharmaceutical company focused on developing best-in-class small molecule therapeutics for chronic cardiometabolic and inflammatory conditions. The company aims to create safer and more effective oral therapies that can be used alone or in combination with GLP-1 receptor agonists to address issues beyond weight management. Eccogene's diverse pipeline includes clinical programs targeting THR-β and SSAO, as well as preclinical programs for metabolic diseases. Their mission is to improve care and expand access to cost-effective medicines for millions of patients worldwide suffering from these diseases.Explore more
Eccogene Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eccogene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Eccogene has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Eccogene is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Eccogene
Earning: See what the market has to say on Eccogene recently announced quarterly report
Check if Eccogene has recently received funding, and reach out quickly before it becomes old news!
Click to see if Eccogene had a recent Job posting/layoffs
Eccogene, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Eccogene launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Eccogene is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eccogene is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eccogene.
Eccogene financials insights
Gather financial insights about Eccogene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$25M
Eccogene Tech Stack
A closer look at the technologies used by Eccogene
See more technologies
Most Recent Scoops
Left Company
Executive Move
Glenn Reicin, Senior Advisor, has recently left the organization and now serves as Chief Financial Officer for Harmony Biosciences.
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Eccogene News & Media
Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide
Late-breaking poster presentation to be reviewed at the upcoming American Diabetes Association’s 85th Scientific Sessions Late-breaking poster presentation to be reviewed at the upcoming American Diabetes Association’s 85th Scientific SessionsEccogene Appoints Dr. Jai Patel as Chief Medical Officer
BOSTON and SHANGHAI, May 01, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced the appointment of Jai Patel, MRCP (UK), as its Chief Medical Officer (CMO), effective immediately.Eccogene Announces Formation of Scientific Advisory Board
Leading cardiometabolic disease experts to support the continued clinical development of the Company’s diverse pipeline of novel oral small molecule candidates Leading cardiometabolic disease experts to support the continued clinical development of the Company’s diverse pipeline of novel oral small molecule candidatesEccogene Announces Positive Phase 1 Data for Oral THR-β Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®
Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signals Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signals
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eccogene
Sign Up For FreeTo access detailed company insights
Eccogene is a clinical stage biopharmaceutical company focused on developing best-in-class small molecule therapeutics for chronic cardiometabolic and inflammatory conditions. The company aims to create safer and more effective oral therapies that can be used alone or in combination with GLP-1 receptor agonists to address issues beyond weight manag... Read More
